MRK
NYSE · Pharmaceuticals
Merck & Co. Inc.
$115.48
+1.61 (+1.41%)
MRK News30 articles
Amazon Ousts Walmart to Top Fortune 500, Reshaping Corporate Peeking Order
Amazon has claimed the top spot on the 2026 Fortune 500, ending Walmart's 13-year run and signaling a shift in corporate power driven by e-commerce, cloud computing, and healthcare.
Amazon Ousts Walmart as Fortune 500 Leader; Regional Giants Shine
Amazon unseats Walmart as Fortune 500 No. 1, breaking a 13-year streak. Erie Insurance rises, New Jersey boasts 15 firms, and New England has over 20 companies on the list.
Dow Slips as Tech Rebound Skips Blue Chips; Focus on CPI, Energy
The Dow slipped 104 points as a tech-led rally lifted the S&P 500 and Nasdaq, but blue chips lagged. Markets now eye Wednesday's CPI data and Middle East energy risks.
SCHD's Heavy Top Holdings Raise Red Flags for Safety Seekers
SCHD's top 10 holdings now make up 43.5% of assets, raising concentration risk. With a 3.24% yield and $95.17B in assets, the fund's safety profile is under scrutiny.
J&J Shares Rise Amid Market Turmoil; Pipeline and Dividend in Focus
Johnson & Johnson shares rose 2.02% on Friday, outperforming the S&P 500, as a Los Angeles jury found the company not negligent in a talc lawsuit.
Merck Shares Jump as New Drug Data Eases Keytruda Concerns
Merck shares surged 4.9% to $120.26 after ASCO data showed its new cancer drug sac-TMT combined with Keytruda improved progression-free survival, reinforcing confidence in the post-Keytruda pipeline.
Pfizer's Cancer Pipeline Takes Center Stage After ASCO Data Dump
Pfizer enters Monday's trading with a wealth of new cancer drug data from ASCO and a $10.5B China partnership, positioning the stock for a potential re-rating.
Dow Hits Record High as Oil Plunges; AI Stocks Take a Breather
The Dow Jones Industrial Average closed at a record high of 50,650.76 on Wednesday, lifted by healthcare and consumer stocks, as oil prices tumbled and AI-related shares cooled.
Tech Stocks Propel S&P 500 and Nasdaq Higher; Dow Slips on Energy and Healthcare Weakness
The Dow slipped 0.26% on Tuesday as UnitedHealth and Chevron weighed, while the S&P 500 and Nasdaq rallied on tech and AI stocks. Oil prices climbed amid geopolitical concerns.
Regeneron Plunges 10% on Melanoma Drug Trial Failure
Regeneron Pharmaceuticals shares dropped 9.8% Monday after its late-stage melanoma drug trial with fianlimab failed to meet its primary endpoint, missing statistical significance versus Merck's Keytruda.
Wall Street Slips as Tech Retreats, Bond Yields Stay Elevated
U.S. stocks declined Monday as technology shares lost momentum ahead of Nvidia's earnings, while rising oil and elevated bond yields kept inflation concerns in focus.
Regeneron Shares Slide After Melanoma Combo Misses Key Goal
Regeneron shares tumbled 11.8% in premarket trading after its melanoma drug combo missed statistical significance on progression-free survival versus Keytruda.
ImmunityBio Secures Exclusive US Rights to Japan BCG Strain for Bladder Cancer
ImmunityBio announced exclusive U.S. rights to Japan BCG Laboratory's Tokyo-172 BCG strain for bladder cancer therapy, with FDA discussions planned. Shares closed at $7.97 Friday, down 2.2%.
J&J Stock Dips on Friday but Posts Weekly Gain; Key Catalysts Ahead
J&J shares fell 1.77% Friday amid a broad selloff but still gained 2.4% for the week. Next week, investors watch pipeline data and a medtech launch.
Merck Closes $53/Share Acquisition of Terns Pharmaceuticals, Stock Ceases Trading
Merck has finalized its $53-per-share cash acquisition of Terns Pharmaceuticals, causing Terns stock to stop trading on Nasdaq. The deal values Terns at $6.7 billion.
Moderna Shares Surge on Hantavirus Vaccine Interest After Andes Virus Outbreak on Cruise Ship
Moderna shares rose nearly 12% after an Andes virus outbreak on a cruise ship drew attention to its early-stage hantavirus vaccine, though WHO rates public risk low.
Moderna Stock Jumps 12% on Hantavirus Vaccine Deal; Flu and Cancer Pipeline in Focus
Moderna shares rose 11.9% to $54.35 after the company disclosed early-stage hantavirus vaccine research with the U.S. Army and Korea University, following a deadly outbreak on the MV Hondius cruise ship.
Dow Jones Slips Below 50,000 as Chip Stocks Drag, Focus Shifts to Jobs Data
The Dow Jones Industrial Average fell below 50,000 on Thursday as chip stocks retreated and investors awaited the monthly jobs report.
Summit Therapeutics Shares Dive 23% After HARMONi-3 Update Disappoints
Summit Therapeutics shares plummeted 23% after an interim HARMONi-3 update for ivonescimab failed to show early benefit. The trial remains blinded, with final PFS data due in late 2026.
Dow Falls as Tariffs Weigh on Blue-Chips, Tech Lifts S&P and Nasdaq
Dow Jones fell 78 points Friday as EU auto tariff worries offset Apple's strong earnings. S&P 500 and Nasdaq hit new highs on tech gains.
Tempus AI Faces Pivotal May with Q1 Results and Inaugural Investor Day
Tempus AI reports Q1 results May 5 and holds its first investor day May 29, with Merck CEO highlighting the partnership. Stock trades near $55.44 with a $9.7B market cap.
Pfizer Gains on FDA Priority Review for Padcev as Pipeline Pivots Post-COVID
Pfizer shares advanced after the FDA granted priority review for its Padcev bladder cancer therapy, setting an August decision. Investors await Q1 results to gauge progress in oncology and obesity drugs against fading COVID sales.
SCHD ETF Approaches 52-Week Peak as Dividend Strategies Regain Favor
The Schwab U.S. Dividend Equity ETF traded near $31.06, close to its 52-week high, with year-to-date gains around 14%. The fund captured a significant portion of the $24.1 billion that flowed into U.S. dividend funds during the first quarter.
SCHD ETF Sees Strong Q1 Inflows After Dividend Hike and Portfolio Overhaul
The Schwab U.S. Dividend Equity ETF (SCHD) reported a 3.3% dividend increase and $4 billion in first-quarter inflows following a significant portfolio reshuffle that boosted healthcare and tech exposure while reducing energy holdings.
SCHD ETF Boosts Healthcare in Rebalance as Dividend Fund Inflows Surge
The Schwab U.S. Dividend Equity ETF (SCHD) increased its healthcare allocation to 18.5% during its yearly portfolio update, adding Abbott Laboratories and UnitedHealth Group. The fund gathered nearly $4 billion in the first quarter as investors poured a total of $24.1 billion into U.S. dividend-focused funds, marking the strongest quarterly start since 2022.
Merck's $6.7B Terns Buyout Anchors Stock Near Offer Price
Merck has agreed to acquire Terns Pharmaceuticals in a $6.7 billion all-cash deal. Terns shares traded at $52.86, close to Merck's $53-per-share offer, as investors weigh the deal's completion.
Merck Acquires Terns Pharma in $6.7B Deal to Fortify Cancer Portfolio
Merck will purchase Terns Pharmaceuticals for $53 per share in cash, a transaction valued at approximately $6.7 billion. The acquisition provides Merck with an experimental leukemia therapy as it prepares for the loss of exclusivity for its blockbuster drug Keytruda.
SCHD ETF Gains Investor Attention Following Annual Rebalance and Dividend Payout
The Schwab U.S. Dividend Equity ETF (SCHD) is drawing renewed interest following its annual portfolio rebalance and a recent dividend distribution. The fund's strategic shift and income profile are being highlighted as key attractions for investors.
ImmunityBio Plunges 21% on FDA Warning Over Anktiva Marketing
ImmunityBio shares tumbled 21.1% following an FDA warning letter alleging false or misleading promotional claims about its cancer therapy Anktiva. The drug generated essentially all of the company's $113 million in 2025 revenue.
J&J Shares Dip on Lupus Drug Fast Track, Investors Eye Legal Risks
Johnson & Johnson shares declined 0.7% to $245.07 Wednesday after the FDA granted Fast Track designation to its lupus drug candidate nipocalimab, lagging behind a strong market advance.